The long and short of it: a new way to analyse ultrashort-, short- and long-chain PFAS simultaneously (part II)

Published: 2-Oct-2025
Analysis

In Part II, one LC-MS/MS method “to detect them all” is introduced and the author, Craig Butt, Senior Manager, Applied Markets, Global Technical Marketing at SCIEX, looks at ways to streamline compliance with evolving global regulations

You need to be a subscriber to read this article.
Click here to find out more.

Along with partner scientists at Phenomenex and York University (Canada), SCIEX has developed a robust and streamlined method for the simultaneous quantification of ultrashort-, short- and long-chain PFAS in water from various sources using a single direct injection LC-MS/MS technique (Figure 2).8

The method utilises the Phenomenex Luna Omega PS C18 column combined with the SCIEX 7500 system mass spectrometry platform (as the even more advanced SCIEX 7500+ system was not available at the time), optimised for high sensitivity and selectivity across a wide range of PFAS chemistries, including emerging and legacy compounds. 

This approach eliminates the need for complex sample preparation steps such as SPE, enabling the direct analysis of water samples with minimal handling and significantly reducing overall processing time and potential contamination. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • SCIEX
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis

The long and short of it: a new way to analyse ultrashort-, short- and long-chain PFAS simultaneously (part I)

Read more
SCIEX PFAS expert, Craig Butt (pictured), explores innovative methods that enable the rapid, sensitive detection and monitoring of ultrashort-, short- and long-chain PFAS in complex environmental matrices such as air and seawater

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    From West to East: building biotech bridges across APAC and the Middle East Amid rising geopolitical uncertainty, US biotech companies are looking beyond tariffs and trade tensions to expand into Asia-Pacific and the Middle East
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    The long and short of it: a new way to analyse ultrashort-, short- and long-chain PFAS simultaneously (part I) SCIEX PFAS expert, Craig Butt (pictured), explores innovative methods that enable the rapid, sensitive detection and monitoring of ultrashort-, short- and long-chain PFAS in complex environmental matrices such as air and seawater
  3. Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).
  4. Shimadzu enhances dual ion source technology with compact LCMS-2050 The system combines high-speed analysis, energy efficiency, and advanced DUIS capability in a compact design
  5. CI Precision CI Precision specialises in the design and manufacture of precision weighing systems for quality assurance in the pharmaceutical manufacturing industry.

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis

The long and short of it: a new way to analyse ultrashort-, short- and long-chain PFAS simultaneously (part I)

SCIEX PFAS expert, Craig Butt (pictured), explores innovative methods that enable the rapid, sensitive detection and monitoring of ultrashort-, short- and long-chain PFAS in complex environmental matrices such as air and seawater
Drug Delivery

The SCIEX BioPhase 8800 uses native fluorescence detection for protein-based CE assays

SCIEX, a global leader in life science analytical technologies, launches new native fluorescence detection on the BioPhase 8800 system
Drug Delivery

Sciex launches the Zenotof 7600+ system at HUPO 2024

New system features cutting-edge data acquisition and strategic collaborations to enhance proteomics
Research & Development

Improving the analysis of RNA medicines: what to expect in 2024

In vitro transcribed (IVT) RNA development has advanced since the first messenger RNA (mRNA) vaccines to prevent COVID-19 entered the market in 2020. Now the focus of similar drug candidates is on other prophylactic vaccines to prevent infectious diseases, including influenza and respiratory syncytial virus (RSV), and therapeutic drugs that might soon be used to treat cancer and other diseases
Analysis

How self-replicating RNA can transform in vitro-transcribed drug development

In vitro-transcribed (IVT) ribonucleic acids (RNAs) are integral to next-generation nucleic acid-based drugs. The recent success of messenger RNA (mRNA)-based vaccines against COVID-19 created new opportunities to untangle their working mechanism, advantages and disadvantages. Kerstin Pohl, Senior Manager, Cell & Gene Therapy and Nucleic Acids, SCIEX, reports
Analysis

SCIEX announces new biotransformation solutions for routine and comprehensive metabolism and biologic catabolism studies

Biotransform solutions use the first commercial software to automate protein catabolite identification and speeds identification of metabolites and catabolites
Analysis

Merck and others pull back from UK: what it means for pharma manufacturing

With pharma giant Merck pulling its own version of Brexit, what can the UK do to retain its drug manufacturing capabilities?
Subscribe now